Compare $MNPR vs $RGNX | Chartloom

Compare

$MNPR vs $RGNX

Monopar Therapeutics Inc · Regenxbio Inc

MNPR

Monopar Therapeutics Inc

RGNX

Regenxbio Inc

Compare $MNPR vs $RGNX

Comparing Monopar Therapeutics Inc and Regenxbio Inc

MNPRMonopar Therapeutics Inc

RGNXRegenxbio Inc

MNPRMonopar Therapeutics Inc

Market cap

$529M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

48.37x

Rev growth (TTM)

—

YTD performance

19.6%

52W performance

-19.9%

FCF yield

-2.3%

RGNXRegenxbio Inc

Market cap

$511M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.95x

Rev growth (TTM)

12.0%

YTD performance

-40.5%

52W performance

-34.0%

FCF yield

-48.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MNPR

RGNX

Detailed metrics comparison

MNPR

Monopar Therapeutics Inc

RGNX

Regenxbio Inc

Market Cap

MNPR$529M

RGNX$511M

Enterprise Value

MNPR$476M

RGNX$656M

Price

MNPR$78.96

RGNX$8.07

P/E Ratio

MNPRN/A

RGNXN/A

P/S Ratio

MNPR0.00x

RGNX2.93x

EV/Sales

MNPR0.00x

RGNX3.76x

EV/EBITDA

MNPR0.00x

RGNX5.30x

P/B Ratio

MNPR4.00x

RGNX6.83x

P/FCF Ratio

MNPRN/A

RGNXN/A

EV/FCF

MNPR-39.10x

RGNX-2.63x

PEG Ratio

MNPRN/A

RGNXN/A

Forward P/E (NTM)

MNPRN/A

RGNXN/A

Forward P/S (NTM)

MNPR48.37x

RGNX5.95x

Revenue (TTM)

MNPR$0

RGNX$174M

Revenue Growth (YoY)

MNPRN/A

RGNX12.0%

Forward Rev Growth

MNPR327.6%

RGNX25.9%

Gross Margin (TTM)

MNPR0.0%

RGNX86.4%

Operating Margin (TTM)

MNPR0.0%

RGNX0.0%

EBITDA Margin (TTM)

MNPR0.0%

RGNX-85.3%

Net Margin (TTM)

MNPR0.0%

RGNX-112.6%

FCF Margin (TTM)

MNPRN/A

RGNX-143.1%

Net Income (TTM)

MNPR$-18M

RGNX$-196M

FCF (TTM)

MNPR$-12M

RGNX$-250M

EPS (TTM)

MNPR-$2.09

RGNX-$3.71

ROE (TTM)

MNPR-1308.0%

RGNX-22007.0%

ROA (TTM)

MNPR-1279.0%

RGNX-4604.0%

ROIC (TTM)

MNPR-1308.0%

RGNX-7179.0%

Cash

MNPR$53M

RGNX$36M

Debt

MNPR$0

RGNX$182M

Net Cash/Debt

MNPR$53M

RGNX$-145M

Current Ratio (TTM)

MNPR33.56x

RGNX2.86x

Quick Ratio (TTM)

MNPR33.56x

RGNX2.71x

Debt/Equity (TTM)

MNPR0.00x

RGNX2.53x

Debt/Assets (TTM)

MNPR0.0%

RGNX0.0%

Interest Coverage (TTM)

MNPRN/A

RGNXN/A

Net Debt/EBITDA (TTM)

MNPR0.00x

RGNX0.00x

Beta

MNPR1.54

RGNX1.21

52W Performance

MNPR-19.9%

RGNX-34.0%

YTD Performance

MNPR19.6%

RGNX-40.5%

% from 52W High

MNPR-36.7%

RGNX-50.2%

% from 52W Low

MNPR57.7%

RGNX47.9%

Asset Turnover (TTM)

MNPR0.00x

RGNX0.41x

FCF Yield (TTM)

MNPR-2.3%

RGNX-48.9%

Earnings Yield (TTM)

MNPR-3.4%

RGNX-38.5%

Dividend Yield (TTM)

MNPRN/A

RGNXN/A

Rule of 40

MNPR0.0

RGNX-131.1

EV/GP/RG

MNPRN/A

RGNX0.15

Ticker research

View MNPR research View RGNX research

Metric	MNPR Monopar Therapeutics Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$529M	$511M
Enterprise Value	$476M	$656M
Price	$78.96	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.93x
EV/Sales	0.00x	3.76x
EV/EBITDA	0.00x	5.30x
P/B Ratio	4.00x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.10x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	48.37x	5.95x
Revenue & Growth
Revenue (TTM)	$0	$174M
Revenue Growth (YoY)	N/A	12.0%
Forward Rev Growth	327.6%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-85.3%
Net Margin (TTM)	0.0%	-112.6%
FCF Margin (TTM)	N/A	-143.1%
Net Income (TTM)	$-18M	$-196M
FCF (TTM)	$-12M	$-250M
EPS (TTM)	-$2.09	-$3.71
ROE (TTM)	-1308.0%	-22007.0%
ROA (TTM)	-1279.0%	-4604.0%
ROIC (TTM)	-1308.0%	-7179.0%
Financial Health
Cash	$53M	$36M
Debt	$0	$182M
Net Cash/Debt	$53M	$-145M
Current Ratio (TTM)	33.56x	2.86x
Quick Ratio (TTM)	33.56x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.21
52W Performance	-19.9%	-34.0%
YTD Performance	19.6%	-40.5%
% from 52W High	-36.7%	-50.2%
% from 52W Low	57.7%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.41x
FCF Yield (TTM)	-2.3%	-48.9%
Earnings Yield (TTM)	-3.4%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View MNPR research	View RGNX research

Valuation

P/S Ratio

MNPR

0.00x

RGNX

2.93x

EV/FCF

MNPR

-39.10x

RGNX

-2.63x

Growth & revenue

Revenue Growth TTM

RGNX

12.0%

Forward Revenue Growth

MNPR

327.6%

RGNX

25.9%

Profitability & performance

Gross Margin

RGNX

86.4%

MNPR

0.0%

ROE

MNPR

-1308.0%

RGNX

-22007.0%

FCF Yield %

MNPR

-2.3%

RGNX

-48.9%

52-Week Performance

MNPR

-19.9%

RGNX

-34.0%

Detailed metrics comparison

MNPR

Monopar Therapeutics Inc

RGNX

Regenxbio Inc

Market Cap

MNPR$529M

RGNX$511M

Enterprise Value

MNPR$476M

RGNX$656M

Price

MNPR$78.96

RGNX$8.07

P/E Ratio

MNPRN/A

RGNXN/A

P/S Ratio

MNPR0.00x

RGNX2.93x

EV/Sales

MNPR0.00x

RGNX3.76x

EV/EBITDA

MNPR0.00x

RGNX5.30x

P/B Ratio

MNPR4.00x

RGNX6.83x

P/FCF Ratio

MNPRN/A

RGNXN/A

EV/FCF

MNPR-39.10x

RGNX-2.63x

PEG Ratio

MNPRN/A

RGNXN/A

Forward P/E (NTM)

MNPRN/A

RGNXN/A

Forward P/S (NTM)

MNPR48.37x

RGNX5.95x

Revenue (TTM)

MNPR$0

RGNX$174M

Revenue Growth (YoY)

MNPRN/A

RGNX12.0%

Forward Rev Growth

MNPR327.6%

RGNX25.9%

Gross Margin (TTM)

MNPR0.0%

RGNX86.4%

Operating Margin (TTM)

MNPR0.0%

RGNX0.0%

EBITDA Margin (TTM)

MNPR0.0%

RGNX-85.3%

Net Margin (TTM)

MNPR0.0%

RGNX-112.6%

FCF Margin (TTM)

MNPRN/A

RGNX-143.1%

Net Income (TTM)

MNPR$-18M

RGNX$-196M

FCF (TTM)

MNPR$-12M

RGNX$-250M

EPS (TTM)

MNPR-$2.09

RGNX-$3.71

ROE (TTM)

MNPR-1308.0%

RGNX-22007.0%

ROA (TTM)

MNPR-1279.0%

RGNX-4604.0%

ROIC (TTM)

MNPR-1308.0%

RGNX-7179.0%

Cash

MNPR$53M

RGNX$36M

Debt

MNPR$0

RGNX$182M

Net Cash/Debt

MNPR$53M

RGNX$-145M

Current Ratio (TTM)

MNPR33.56x

RGNX2.86x

Quick Ratio (TTM)

MNPR33.56x

RGNX2.71x

Debt/Equity (TTM)

MNPR0.00x

RGNX2.53x

Debt/Assets (TTM)

MNPR0.0%

RGNX0.0%

Interest Coverage (TTM)

MNPRN/A

RGNXN/A

Net Debt/EBITDA (TTM)

MNPR0.00x

RGNX0.00x

Beta

MNPR1.54

RGNX1.21

52W Performance

MNPR-19.9%

RGNX-34.0%

YTD Performance

MNPR19.6%

RGNX-40.5%

% from 52W High

MNPR-36.7%

RGNX-50.2%

% from 52W Low

MNPR57.7%

RGNX47.9%

Asset Turnover (TTM)

MNPR0.00x

RGNX0.41x

FCF Yield (TTM)

MNPR-2.3%

RGNX-48.9%

Earnings Yield (TTM)

MNPR-3.4%

RGNX-38.5%

Dividend Yield (TTM)

MNPRN/A

RGNXN/A

Rule of 40

MNPR0.0

RGNX-131.1

EV/GP/RG

MNPRN/A

RGNX0.15

Ticker research

View MNPR research View RGNX research

Metric	MNPR Monopar Therapeutics Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$529M	$511M
Enterprise Value	$476M	$656M
Price	$78.96	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.93x
EV/Sales	0.00x	3.76x
EV/EBITDA	0.00x	5.30x
P/B Ratio	4.00x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-39.10x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	48.37x	5.95x
Revenue & Growth
Revenue (TTM)	$0	$174M
Revenue Growth (YoY)	N/A	12.0%
Forward Rev Growth	327.6%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-85.3%
Net Margin (TTM)	0.0%	-112.6%
FCF Margin (TTM)	N/A	-143.1%
Net Income (TTM)	$-18M	$-196M
FCF (TTM)	$-12M	$-250M
EPS (TTM)	-$2.09	-$3.71
ROE (TTM)	-1308.0%	-22007.0%
ROA (TTM)	-1279.0%	-4604.0%
ROIC (TTM)	-1308.0%	-7179.0%
Financial Health
Cash	$53M	$36M
Debt	$0	$182M
Net Cash/Debt	$53M	$-145M
Current Ratio (TTM)	33.56x	2.86x
Quick Ratio (TTM)	33.56x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.54	1.21
52W Performance	-19.9%	-34.0%
YTD Performance	19.6%	-40.5%
% from 52W High	-36.7%	-50.2%
% from 52W Low	57.7%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.41x
FCF Yield (TTM)	-2.3%	-48.9%
Earnings Yield (TTM)	-3.4%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View MNPR research	View RGNX research